Chapter 3 Glucuronidation-Dependent Toxicity and Bioactivation

Advances in Molecular Toxicology

Volumn 2, Issue C, 2008, Pages 57-86

  Sallustio, Benedetta C ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINE; DICLOFENAC; HYDROXAMIC ACID; IRINOTECAN; MORPHINE; MORPHINE 6 GLUCURONIDE; MYCOPHENOLIC ACID; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENACETIN;

BLADDER CANCER; BONE MARROW SUPPRESSION; COLON CANCER; DIARRHEA; GASTROINTESTINAL TOXICITY; GENOTOXICITY; GLUCURONIDATION; HUMAN; HYDROPHILICITY; IMMUNOBLOTTING; LIVER TOXICITY; LUNG SMALL CELL CANCER; LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; RECTUM CANCER; RENAL SYMPTOMS; REVIEW;

EID: 76449090680     PISSN: 18720854     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1872-0854(07)02003-6     Document Type: Review

References (177)

1. Zia-Amirhosseini P., Spahn-Langguth H., and Benet L.Z. Bioactivation by glucuronide-conjugate formation. Adv. Pharmacol. 27 (1994) 385-397
2. Ritter J.K. Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem. Biol. Interact. 129 (2000) 171-193
3. King C.D., Rios G.R., Green M.D., and Tephly T.R. UDP-Glucuronosyltransferases. Curr. Drug. Metab. 1 (2000) 143-161
4. Tukey R.H., and Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu. Rev. Pharmacol. Toxicol. 40 (2000) 581-616
5. Wells P.G., Mackenzie P.I., Choudhury J.R., Guillemette C., Gregory P.A., Ishii Y., Hansen A.J., Kessler F.K., Kim P.M., Choudhury N.R., and Ritter J.K. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug. Metab. Dispos. 32 (2004) 281-290
6. Frances B., Gout R., Monsarrat B., Cros J., and Zajac J.-M. Further evidence that morphine-6β-glucuronide is a more potent opioid agonist than morphine. J. Pharmacol. Exp. Ther. 262 (1992) 25-31
7. Osborne R., Thompson P., Joel S., Trew D., Patel N., and Slevin M. The analgesic activity of morphine-6-glucuronide. Br. J. Clin. Pharmacol. 34 (1992) 130-138
8. Bauer T.M., Ritz R., Haberthur C., Ha H.R., Hunkeler W., Sleight A.J., Scollo-Lavizzari G., and Haefeli W.E. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 346 (1995) 145-147
9. Scholz H., and Schmitz W. Positive inotropic effects of digitoxin- and digoxin-glucuronide in human isolated ventricular heart muscle preparations. Basic Res. Cardiol. 79 (1984) 134-139
10. Olson J.A., Moon R.C., Anders M.W., Fenselau C., and Shane B. Enhancement of biological activity by conjugation reactions. J. Nutr. 122 (1992) 615-624
11. Wieland E., Shipkova M., Schellhaas U., Schutz E., Niedmann P.E., Armstrong V.W., and Oellerich M. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects. Clin. Biochem. 33 (2000) 107-113
12. Milne R.W., Nation R.L., and Somogyi A.A. Disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev. 28 (1996) 345-472
13. Meyers M., Slikker W., and Vore M. Steroid D-ring glucuronides: characterisation of a new class of cholestatic agents in the rat. J. Pharmacol. Exp. Ther. 218 (1981) 63-73
14. Oelberg D.G., Chari M.V., Little J.M., Adcock E.W., and Lester R. Lithocholate glucuronide is a cholestatic agent. J. Clin. Invest. 73 (1984) 1507-1514
15. Takikawa H., Ohki H., Sano N., Kasama T., and Yamanaka M. Cholestasis induced by lithocholate and its glucuronide: their biliary excretion and metabolism. Biochim. Biophys. Acta 1081 (1991) 39-44
16. Krijgsheld K.R., Koster H.J., Scholtens E., and Mulder G.J. Cholestatic effect of harmol glucuronide in the rat. Prevention of harmol-induced cholestasis by increased formation of harmol sulfate. J. Pharmacol. Exp. Ther. 221 (1982) 731-734
17. Meyers M., Slikker W., Pascoe G., and Vore M. Characterisation of cholestasis induced by estradiol-17β-D-glucuronide in the rat. J. Pharmacol. Exp. Ther. 214 (1980) 87-93
18. Slikker W., Vore M., Bailey J.R., Meyers M., and Montgomery C. Hepatotoxic effects of estradiol-17β-D-glucuronide in the rat and monkey. J. Pharmacol. Exp. Ther. 225 (1983) 138-143
19. Morikawa A., Goto Y., Suzuki H., Hirohashi T., and Sugiyama Y. Biliary excretion of 17β-estradiol 17β-D-glucuronide is predominantly mediated by cMOAT/MRP2. Pharm. Res. 17 (2000) 546-552
20. Huang L., Smit J.W., Meijer D.K.F., and Vore M. Mrp2 is essential for estradiol-17β(β-D-glucuronide)-induced cholestasis in rats. Hepatology 32 (2000) 66-72
21. Takikawam H., Minagawa K., Sano N., and Yamanaka M. Lithocholate-3-O-glucuronide-induced cholestasis: a study with congenital hyperbilirubinemic rats and effects of ursodeoxycholate conjugates. Dig. Dis. Sci. 38 (1993) 1543-1548
22. Mottino A.D., Crocenzi F.A., Sanchez Pozzi E.J., Veggi L.M., Roma M.G., and Vore M. Role of microtubules in estradiol-17β-D-glucuronide-induced alteration of canalicular Mrp2 localization and activity. Am. J. Gastrointest. Liver Physiol. 288 (2005) G327-G336
23. Vu D.D., Tuchweber B., Plaa G.L., and Yousef I.M. Pathogenesis of lithocholate-induced intrahepatic cholestasis: role of glucuronidation and hydroxylation of lithocholate. Biochim. Biophys. Acta. 1126 (1992) 53-59
24. Wright A.W.E., and Dickinson R.G. Abolition of valproate-derived choleresis in the Mrp2 transporter-deficient rat. J. Pharmacol. Exp. Ther. 310 (2004) 584-588
25. Mahagita C., Tanphichai K., Suksamrarn A., Ballatori N., and Piyachaturawat P. 4-Hydroxyacetophenone-induced choleresis is mediated by the Mrp2-dependent biliary secretion of its glucuronide conjugate. Pharm. Res. 23 (2006) 2603-2610
26. Paul H., Illing A., and Wilson I.D. pH dependent formation of β-glucuronidase resistant conjugates from the biosynthetic ester glucuronide of isoxepac. Biochem. Pharmacol. 30 (1981) 3381-3384
27. Hasegawa J., Smith P.C., and Benet L.Z. Apparent intramolecular acyl migration of zomepirac glucuronide. Drug Metab. Dispos. 10 (1982) 469-473
28. Dickinson R.G., Hooper W.D., and Eadie M.J. pH-Dependent rearrangement of the biosynthetic ester glucuronide of valproic acid to β-glucuronidase-resistant forms. Drug Metab. Dispos. 12 (1984) 247-252
29. Rachmel A., Hazelton G.A., Yergey A.L., and Liberato D.J. Furosemide 1-O-acyl glucuronide: in vitro biosynthesis and pH-dependent isomerization to β-glucuronidase-resistant forms. Drug Metab. Dispos. 13 (1985) 705-710
30. Shore L.J., Fenselau C., King A.R., and Dickinson R.G. Characterisation and formation of the glutathione conjugate of clofibric acid. Drug Metab. Dispos. 23 (1995) 119-123
31. Olsen J., Bjornsdottir I., Tjornelund J., and Hansen S.H. Chemical reactivity of the naproxen acyl glucuronide and the naproxen coenzyme A thioester towards binucleophiles. J. Pharm. Biomed. Anal. 29 (2002) 7-15
32. Li C., Benet L.Z., and Grillo M.P. Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem. Res. Toxicol. 15 (2002) 1309-1317
33. Grillo M.P., Knutson C.G., Sanders P.E., Waldon D.J., Hua F., and Ware J.A. Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab. Dispos. 31 (2003) 1327-1336
34. Ding A., Zia-Amirhosseini P., McDonagh A.F., Burlingame A.L., and Benet L.Z. Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab. Dispos. 23 (1995) 369-376
35. Qui Y., Burlingame A.L., and Benet L.Z. Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Drug Metab. Dispos. 26 (1998) 246-256
36. 9-11-carboxytetrahydrocannabinol glucuronide. Chem. Res. Toxicol. 2 (1989) 316-324
37. Nicholls A.W., Akira K., Lindon J.C., Farrant R.D., Wilson I.D., Killick D.A., and Nicholson J.K. NMR spectroscopic and theoretical chemistry studies on the internal acyl migration reactions of the 1-O-acyl-β-D-glucopyranuronate conjugates of 2-, 3-, and 4-(trifluoromethyl)benzoic acids. Chem. Res. Toxicol. 9 (1996) 1414-1424
38. 13C labelling and nuclear magnetic resonance spectroscopy. Drug Metab. Dispos. 26 (1998) 457-464
39. Mortensen R.W., Sidelmann U.G., Tjornelund J., and Hansen S.H. Stereospecific pH-dependent degradation kinetics of R- and S-naproxen-β-1-O-acyl-glucuronide. Chirality 14 (2002) 305-312
40. Sinclair K.A., and Caldwell J. The formation of β-glucuronidase resistant glucuronides by the intramolecular rearrangement of glucuronic acid conjugates at mild alkaline pH. Biochem. Pharmacol. 31 (1982) 953-957
41. Akira K., Uchijima T., and Hashimoto T. Rapid internal acyl migration and protein binding of synthetic probenecid glucuronides. Chem. Res. Toxicol. 15 (2002) 765-772
42. Smith P.C., and Wang C. Nonenzymic glycation of albumin by acyl glucuronides in vitro: comparisons of reactions with reducing sugars. Biochem. Pharmacol. 44 (1992) 1661-1668
43. Sallustio B.C., DeGraaf Y.C., Weekley J.S., and Burcham P.C. Bioactivation of carboxylic acid compounds by UDP-glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity. Chem. Res. Toxicol. 19 (2006) 683-691
44. Blanckaert N., Compernolle F., Leroy P., Van Houtte R., Fevery J., and Heirwegh K.P.M. The fate of bilirubin-IXα glucuronide in cholestasis and during storage in vitro: intramolecular rearrangement to positional isomers of glucuronic acid. Biochem. J. 171 (1978) 203-214
45. Compernolle F., Van Hees G.P., Blanckaert N., and Heirwegh K.P.M. Glucuronic acid conjugates of bilirubin-IXα in normal bile compared with post-obstructive bile: transformation of the 1-O-acylgucuronide into 2-, 3- amd 4-O-acylglucuronides. Biochem. J. 171 (1978) 185-201
46. Faed E.M. Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. Drug Metab. Rev. 15 (1984) 1213-1249
47. Spahn-Langguth H., and Benet L.Z. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism. Drug Metab. Rev. 24 (1992) 5-48
48. Hayball P.J. Formation and reactivity of acyl glucuronides: the influence of chirality. Chirality 7 (1995) 1-9
49. Sallustio B.C., Sabordo L., Evans A.M., and Nation R.L. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr. Drug Metab. 1 (2000) 163-180
50. Bailey M.J., and Dickinson R.G. Acyl glucuronide reactivity in perspective: biological consequences. Chem. Biol. Interact. 145 (2003) 117-137
51. Hyneck M.L., Munafo A., and Benet L.Z. Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide. Drug Metab. Dispos. 16 (1988) 322-324
52. Sallustio B.C., Fairchild B.A., and Pannall P.R. Interaction of human serum albumin with the electrophilic metabolite 1-O-gemfibrozil-β-D-glucuronide. Drug Metab. Dispos. 25 (1997) 55-60
53. Williams A.M., Worrall S., De Jersey J., and Dickinson R.G. Studies on the reactivity of acyl glucuronides. III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans. Biochem. Pharmacol. 43 (1992) 745-755
54. Benet L.Z., Spahn-Langguth H., Iwakawa S., Volland C., Mizuma T., Mayer S., Mutschler E., and Lin E.T. Predictability of the covalent binding of acidic drugs in man. Life Sci. 53 (1993) 141-146
55. King A.R., and Dickinson R.G. Studies on the reactivity of acyl glucuronides. I. Phenolic glucuronidation of isomers of diflunisal acyl glucuronide in the rat. Biochem. Pharmacol. 42 (1991) 2289-2299
56. Iwaki M., Bischer A., Nguyen A.C., McDonagh A.F., and Benet L.Z. Stereoselective disposition of naproxen glucuronide in the rat. Drug Metab. Dispos. 23 (1995) 1099-1103
57. Wang M., and Dickinson R.G. Disposition and covalent binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat liver. Drug Metab. Dispos. 26 (1998) 98-104
58. Sallustio B.C., Fairchild B.A., Shanahan K., Evans A.M., and Nation R.L. Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver. Drug Metab. Dispos. 24 (1996) 984-989
59. Grubb N., Weil A., and Caldwell J. Studies on the in vitro reactivity of clofibryl and fenofibryl glucuronides. Biochem. Pharmacol. 46 (1993) 357-364
60. Iwaki M., Ogiso T., Inagawa S., and Kakehi K. In vitro regioselective stability of β-1-O- and 2-O-acyl glucuronides of naproxen and their covalent binding to human serum albumin. J. Pharm. Sci. 88 (1998) 52-57
61. Ojingwa J.C., Spahn-Langguth H., and Benet L.Z. Irreversible binding of tolmetin to macromolecules via its glucuronide: binding to blood constituents, tissue homogenates and subcellular fractions in vitro. Xenobiotica 24 (1994) 495-506
62. Wang M., and Dickinson R.G. Bile duct ligation promotes covalent drug-protein adduct formation in plasma but not in liver of rats given zomepirac. Life Sci. 68 (2000) 525-537
63. Watt J.A., and Dickinson R.G. Effects of blockage of urine and/or bile flow on diflunisal conjugation and disposition in rats. Xenobiotica 20 (1990) 835-845
64. Dickinson R.G., Verbeeck R.K., and King A.R. Absence of phenolic glucuronidation and enhanced hydroxylation of diflunisal in the homozygous Gunn rat. Xenobiotica 21 (1991) 1535-1546
65. Dickinson R.G., King A.R., McKinnon G.E., Hooper W.D., Eadie M.J., and Herkes G.K. Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisal. Br. J. Clin. Pharmacol. 35 (1993) 609-613
66. Dickinson R.G., and King A.R. Rearrangement of diflunisal acyl glucuronide into its β-glucuronidase-resistant isomers facilitates transport through the small intesitne to the colon of the rat. Life Sci. 70 (2001) 25-36
67. Dickinson R.G., Kluck R.M., Hooper W.D., Patterson M., Chalk J.B., and Eadie M.J. Rearrangement of valproate glucuronide in a patient with drug-associated hepatobiliary and renal dysfunction. Epilepsia 26 (1985) 589-593
68. Castillo M., Lam Y.W.F., Dooley M.A., Stahl E., and Smith P.C. Disposition and covalent binding of ibuprofen and its acyl glucuronides in the elderly. Clin. Pharmacol. Ther. 57 (1995) 636-644
69. Castillo M., and Smith P.C. Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab. Dispos. 23 (1995) 566-572
70. Irving C.C. Metabolic activation of N-hydroxy compounds by conjugation. Xenobiotica 1 (1971) 387-398
71. Hanna P.E., and Banks R.B. Arylhydroxylamines and arylhydroxamic acids: conjugation reactions. In: Anders M.W. (Ed). Bioactivation of Foreign Compounds (1985), Academic Press Inc, New York
72. Hill J.T., and Irving C.C. Biosynthesis and studies of the alkaline sensitivity of the NO-glucuronide of the carcinogen N-2-fluorenylacethydroxamic acid. Biochemistry 6 (1967) 3816-3821
73. Irving C.C., and Russell L.T. Synthesis of the O-glucuronide of N-2-fluorenylhydroxylamine. Reactions with nucleic acids and with guanosine 5′-monophosphate. Biochemistry 9 (1970) 2471-2476
74. Babu S.R., Lakshmi V.M., Hsu F.F., and Zenser T.V. Glucuronidation of N-hydroxy metabolites of N-acetylbenzidine. Carcinogenesis 16 (1995) 3069-3074
75. Babu S.R., Lakshmi V.M., Huang G.P.-W., Zenser T.V., and Davis B.B. Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites. Biochem. Pharmacol. 51 (1996) 1679-1685
76. Ciotti M., Lakshmi V.M., Basu N., Davis B.B., Owens I.S., and Zenser T.V. Glucuronidation of benzidine and its metabolites by cDNA-expressed human UDP-glucuronosyltransferases and pH stability of glucuronides. Carcinogenesis 20 (1999) 1963-1969
77. Van Breemen R.B., and Fenselau C. Acylation of albumin by 1-O-acyl glucuronides. Drug Metab. Dispos. 13 (1985) 318-320
78. Watt J.A., and Dickinson R.G. Reactivity of diflunisal acyl glucuronide in human and rat plasma and albumin solutions. Biochem. Pharmacol. 39 (1990) 1067-1075
79. Munafo A., McDonagh A.F., Smith P.C., and Benet L.Z. Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro. Pharm. Res. 7 (1990) 21-27
80. Dubois N., Lapicque F., Maurice M.-H., Pritchard M., Fournel-Gigleux S., Magdalou J., Abiteboul M., Siest G., and Netter P. In vitro irreversible binding of ketoprofen glucuronide to plasma proteins. Drug Metab. Dispos. 21 (1993) 617-623
81. Mayer S., Mutschler E., Benet L.Z., and Spahn-Langguth H. In vitro and in vivo irreversible plasma protein binding of beclobric acid enantiomers. Chirality 5 (1993) 120-125
82. Smith P.C., and Liu J.H. Covalent binding of suprofen to renal tissue of rat correlates with excretion of its acyl glucuronide. Xenobiotica 25 (1995) 531-540
83. Kretz-Rommel A., and Boelsterli U.A. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Drug Metab. Dispos. 22 (1994) 956-961
84. Hargus S.J., Amouzedeh H.R., Pumford N.R., Myers T.G., McCoy S.C., and Pohl L.R. Metabolic activation and immunochemical localisation of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. 7 (1994) 575-582
85. Porubek D.J., Grillo M.P., and Baille T.A. The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated hepatocytes. Drug Metab. Dispos. 17 (1989) 123-130
86. Kretz-Rommel A., and Boelsterli U.A. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 120 (1993) 155-161
87. Kretz-Rommel A., and Boelsterli U.A. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis. Mol. Pharmacol. 45 (1994) 237-244
88. McGurk K.A., Remmel R.P., Hosagrahara V.P., Tosh D., and Burchell B. Reactivity of mefenamic acid 1-O-acyl glucuronide with proteins in vitro and ex vivo. Drug Metab. Dispos. 24 (1996) 842-849
89. Terrier N., Benoit E., Senay C., Lapique F., Radominska-Pandya A., Magdalou J., and Fournel-Gigleux S. Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide. Mol. Pharmacol. 56 (1999) 226-234
90. Somchit N., Ramsay L.A., Kenna J.G., and Caldwell J. Glucuronidation mediates hepatic protein adduct formation from diclofenac, but not ibuprofen, in rats: a potential mechanism of hepatotoxicity. Br. J. Clin. Pharmacol. 46 (1998) 304P-305P
91. Li C., Grillo M.P., and Benet L.Z. In vivo mechanistic studies on the metabolic activation of 2-phenylpropionic acid in rat. J. Pharmacol. Exp. Ther. 305 (2003) 250-256
92. Ruelius H.W., Kirkman S.K., Young E.M., and Janssen F.W. Reactions of oxaprozin-1-O-acyl glucuronide in solutions of human plasma and albumin. Adv. Exp. Med. Biol. 197 (1986) 431-441
93. Smith P.C., Benet L.Z., and McDonagh A.F. Covalent binding of zomepirac glucuronide to proteins: evidence for a Schiff base mechanism. Drug Metab. Dispos. 18 (1990) 639-644
94. Smith P.C., Song W.Q., and Rodriguez R.J. Covalent binding of etodolac acyl glucuronide to albumin in vitro. Drug Metab. Dispos. 20 (1992) 962-965
95. Smith P.C., and Liu J.H. Covalent binding of suprofen acyl glucuronide to albumin in vitro. Xenobiotica 23 (1993) 337-348
96. Wang J., Davis M., Li F., Azam F., Scatina J., and Talaat R. A novel approach for predicting acyl glucuronide reactivity via Schiff base formation: development of rapidly formed peptide adducts for LC/MS/MS measurements. Chem. Res. Toxicol. 17 (2004) 1206-1216
97. Ding A., Ojingwa J.C., McDonagh A.F., Burlingame A.L., and Benet L.Z. Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry. Proc. Natl. Acad Sci. U.S.A. 90 (1993) 3797-3801
98. Zia-Amirhosseini P., Ding A., Burlingame A.L., McDonagh A.F., and Benet L.Z. Synthesis and mass-spectrometric charaterisation of human serum albumins modified by covalent binding of two non-steroidal anti-inflammatory drugs: tolmetin and zomepirac. Biochem. J. 311 (1995) 431-435
99. Liu J.H., Marquez C.D., Weintraub S.T., and Smith P.C. Reactions of acyl glucuronides with insulin in vitro: identification of an imine mechanism by electrospray ionization mass spectrometry. Pharm. Res. 15 (1998) 343-346
100. Wells D.S., Janssen F.W., and Ruelius H.W. Interactions between oxaprozin glucuronide and human serum albumin. Xenobiotica 17 (1987) 1437-1449
101. Williams A.M., and Dickinson R.G. Studies on the reactivity of acyl glucuronides. IV Modulation of reversible and covalent interaction of diflunisal acyl glucuronide and its isomers with human plasma protein in vitro. Biochem. Pharmacol. 47 (1994) 457-467
102. Bailey M.J., Worrall S., de Jersey J., and Dickinson R.G. Zomepirac acyl glucuronide covalently modifies tubulin in vitro and in vivo and inhibits its assembly in an in vitro system. Chem. Biol. Interact. 115 (1998) 153-166
103. Chiou Y., Tomer K.B., and Smith P.C. Effect of nonenzymatic glycation of albumin and superoxide dismutase by glucuronic acid and suprofen acyl glucuronide on their functions in vitro. Chem. Biol. Interact. 121 (1999) 141-159
104. Wang M., Gorrell M.D., McCaughan G.W., and Dickinson R.G. Dipeptidyl peptidase IV is a target for covalent adduct formation with the acyl glucuronide metabolite of the anti-inflammatory drug zomepirac. Life Sci. 68 (2001) 785-797
105. Hargus S.J., Martin B.M., George J.W., and Pohl L.R. Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. 8 (1995) 993-996
106. Weiss J.S., Gautam A., Lauff J.J., Sudberg M.W., Jatlow P., Boyer J.L., and Seligson D. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N. Engl. J. Med. 3 (1983) 147-150
107. Smith P.C., McDonagh A.F., and Benet L.Z. Irreversible binding of zomepirac to plasma protein in vitro and in vivo. J. Clin. Invest. 77 (1986) 934-939
108. Hyneck M.L., Smith P.C., Munafo A., McDonagh A.F., and Benet L.Z. Disposition and irreversible plasma protein binding of tolmetin in humans. Clin. Pharmacol. Ther. 44 (1988) 107-114
109. McKinnon G.E., and Dickinson R.G. Covalent binding of diflunisal and probenecid to plasma protein in humans: persistence of the adducts in the circulation. Res. Commun. Chem. Pathol. Pharmacol. 66 (1989) 339-354
110. Sallustio B.C., Knights K.M., Roberts B.J., and Zacest R. In vivo covalent binding of clofibric acid to human plasma proteins and rat liver proteins. Biochem. Pharmacol. 42 (1991) 1421-1425
111. Volland C., Sun H., Dammeyer J., and Benet L.Z. Stereoselective degradation of the fenoprofen acyl glucuronide enantiomers and irreversible binding to plasma protein. Drug Metab. Dispos. 19 (1991) 1080-1086
112. Munafo A., Hyneck M.L., and Benet L.Z. Pharmacokinetics and irreversible binding of tolmetin and its glucuronic acid esters in the elderly. Pharmacology 47 (1993) 309-317
113. Zia-Amirhosseini P., Ojingwa J.C., Spahn-Langguth H., McDonagh A.F., and Benet L.Z. Enhanced covalent binding of tolmetin to proteins in humans after multiple dosing. Clin. Pharmacol. Ther. 55 (1994) 21-27
114. Dickinson R.G., Baker P.V., and King A.R. Studies on the reactivity of acyl glucuronides-IV. Salicyl acyl glucuronide reactivity in vitro and covalent binding of salicylic acid to plasma protein of humans taking aspirin. Biochem. Pharmacol. 47 (1994) 469-476
115. Sallustio B.C., and Foster D.J.R. Reactivity of gemfibrozil 1-O-β-acyl glucuronide. Pharmacokinetics of covalently bound gemfibrozil-protein adducts. Drug Metab. Dispos. 23 (1995) 892-899
116. Dahms M., and Spahn-Langguth H. Covalent binding of acidic drugs via reactive intermediates: detection of benoxaprofen and flunoxaprofen protein aducts in biological material. Pharmazie 51 (1996) 874-881
117. King A.R., and Dickinson R.G. Studies on the reactivity of acyl glucuronides-IV Covalent binding of diflunisal to tissues of the rat. Biochem. Pharmacol. 45 (1993) 1043-1047
118. Pumford N.R., Myers T.G., Davila J.C., Highet R.J., and Pohl L.R. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. 6 (1993) 147-150
119. Bailey M.J., and Dickinson R.G. Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Chem. Res. Toxicol. 9 (1996) 659-666
120. Wade L.T., Kenna J.G., and Caldwell J. Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chem. Res. Toxicol. 10 (1997) 546-555
121. Ware J.A., Graf M.L.M., Martin B.M., Lustberg L.R., and Pohl L.R. Immunochemical detection and identification of protein adducts of diclofenac in the small intestine of rats: possible role in allergic reactions. Chem. Res. Toxicol. 11 (1998) 164-171
122. Seitz S., Kretz-Rommel A., Oude Elferink R.P.J., and Boelsterli U.A. Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (mrp2). Chem. Res. Toxicol. 11 (1998) 513-519
123. Siraki A.G., Chevaldina T., and O'Brien P.J. Application of quantitative structure-toxicity relationships for acute NSAID cytotoxicity in rat hepatocytes. Chem. Biol Interact. 151 (2005) 177-191
124. Masubuchi Y., Saito H., and Hoire T. Structural requirements for the hepatotoxicity of nonsteroidal anti-inflammatory drugs in isolated hepatocytes. J. Pharmacol. Exp. Ther. 287 (1998) 208-213
125. Mahmud T., Rafi S.S., Scott D.L., Wrigglesworth J.M., and Bjarnason I. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. Arthritis Rheum. 39 (1996) 1998-2003
126. Zia-Amirhosseini P., Harris R.Z., Brodsky F.M., and Benet L.Z. Hypersensitivity to nonsteroidal anti-inflammatory drugs. Nature Med. 1 (1995) 2-4
127. Worrall S., and Dickinson R.G. Rat serum albumin modified by diflunisal acyl glucuronide is immunogenic in rats. Life Sci. 56 (1995) 1921-1930
128. Kretz-Rommel A., and Boelsterli U.A. Cytotoxic activity of T cells and non-T cells from diclofenac-immunised mice against cultured synergistic hepatocytes exposed to diclofenac. Hepatology 22 (1995) 213-222
129. Bougie D., Johnson S.T., Weitekamp L.A., and Aster R.H. Sensitivity to a metabolite of diclofenac as a cause of acute immune hemolytic anemia. Blood 90 (1997) 407-413
130. Miller E.C., Lotlikar P.D., Miller J.A., Butler B.W., Irving C.C., and Hill J.T. Reactions in vitro of some nucleophiles with the glucuronide of the carcinogen N-hydroxy-2-acetylaminofluorene. Mol. Pharmacol. 4 (1968) 147-154
131. Lee A.T., and Cerami A. In vitro and in vivo reactions of nucleic acids with reducing sugars. Mutat. Res. 238 (1990) 185-191
132. Baynes J.W. The Maillard hypothesis on aging: time to focus on DNA. Ann. N Y Acad. Sci. 959 (2002) 360-367
133. Sallustio B.C., Harkin L.A., Mann M.C., Krivickas S.J., and Burcham P.C. Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcionogenicity of the parent aglycones. Toxicol. Appl. Pharmacol. 147 (1997) 459-464
134. Ghaoui R., Sallustio B.C., Burcham P.C., and Fontaine F.R. UDP-glucuronosyltransferase-dependent bioactivation of clofibric acid to a DNA-damaging intermediate in mouse hepatocytes. Chem. Biol. Interact. 145 (2003) 201-211
135. H.T. Southwood, Y.C. DeGraaf, P.I. Mackenzie, J.O. Miners, P.C. Burcham, B.C. Sallustio, Carboxylic acid drug-induced DNA nicking in HK293 cells expressing human UDP-glucuronosyltransferases: role of acyl glucuronide metabolites and glycation pathways, Chem. Res. Toxicol. (in press, 2007).
136. Reisenbichler H., and Eckl P. Genotoxic effects of selected peroxisome proliferators. Mutat. Res. 286 (1993) 135-144
137. Reddy J.K., Azarnoff D.L., and Hignite C.E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283 (1980) 397-398
138. Oliver M.F., Heady J.A., Morris J.N., and Cooper J. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J. 40 (1978) 1069-1118
139. Oliver M.F., Heady J.A., Morris J.N., and Cooper J. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 23 August (1980) 379-385
140. Ashby J., Brady A., Elcombe C.R., Elliot B.M., Ishamael J., Odum J., Tugwood J.D., Kettle S., and Purchase I.F.H. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Human Exp. Toxicol. 13 (1994) S1-S117
141. National Toxicology Program. NTP toxicology and carcinogenesis studies of probenecid (CAS No. 57-66-9) in F344/N rats and B6C3F1 mice (Gavage Studies). Natl. Toxicol. Program Tech. Rep. Ser. 395 (1991) 1-215
142. Abraham J. Regulating the cancer-inducing potential of non-steroidal anti-inflammatory drugs: some lessons from the 1970s and 1980s. Soc. Sci. Med. 46 (1998) 39-51
143. Irving C.C., Veazey R.A., and Hill J.T. Reaction of the glucuronide of the carcinogen N-hydroxy-2-acetylaminofluorene with nucleic acids. Biochim. Biophys. Acta 179 (1969) 189-198
144. Irving C.C., Veazey R.A., and Russell L.T. Possible role of the glucuronide conjugate in the biochemical mechanism of binding of the carcinogen N-hydroxy-2-acetylaminofluorene to rat-liver deoxyribonucleic acid. Chem. -Biol. Interact. 1 (1969) 19-26
145. Irving C.C. Influence of the aryl group on the reaction of glucuronides of N-arylacethydroxamic acids with polynucleotides. Cancer Res. 37 (1977) 524-528
146. Irving C.C., and Wiseman R. Studies on the carcinogenicity of the glucuronides of N-hydroxy-2-acetylaminofluorene and N-2-fluorenylhydroxylamine in the rat. Cancer Res. 31 (1971) 1645-1648
147. Kamataki T., Suzuki A., Kushida H., Iwata H., Watanabe M., Nohmi T., and Fujita K. Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines. Cancer Lett. 143 (1999) 113-116
148. Fujita K., Mogami A., Hayashi A., and Kamataki T. Establishment of a Salmonella strain expressing catalytically active human UDP-glucuronosyltransferase 1A1 (UGT1A1). Life Sci. 66 (2000) 1955-1967
149. Tukey R.H., and Strassburg C.P. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol. Pharmacol. 59 (2001) 405-414
150. Haimeur A., Conseil G., Deeley R.G., and Cole S.P.C. The MRP-related and BCRP/ABCG2 mutidrug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. 5 (2004) 21-53
151. Treinen-Molsen M., and Kanz M.F. Intestinal tract injury by drugs: importance of metabolite delivery by the yellow bile road. Pharmacol. Ther. 112 (2006) 649-667
152. Hecht J.R. Gastrointestinal toxicity of irinotecan. Oncology 12 Suppl 6 (1998) 72-78
153. Lokiec F., Canal P., Gay C., Chatelut E., Armand J.-P., Roche H., Bugat R., Goncalves E., and Mathieu-Boue A. Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine. Cancer Chemother. Pharmacol. 36 (1995) 79-82
154. Mathijssen R.H.J., van Alphen R.J., Verweij J., Loos W.J., Stoter G., and Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7 (2001) 2182-2194
155. Iyer L., Ramirez J., Shepard D.R., Bingham C.M., Hossfeld D.-K., Ratain M.J., and Mayer U. Biliary transport of irinotencan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol. 49 (2002) 336-341
156. Chu X.-Y., Kato Y., Niinuma K., Sudo K.-I., Hakusi H., and Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther. 281 (1997) 304-314
157. Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai E., Yokoi T., and Kamataki T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumour camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res. 56 (1996) 3752-3757
158. Takasuna K., Hagiwara T., Hirohashi M., Kato M., Nomura M., Nagai E., Yokoi T., and Kamataki T. Inhibition of intestinal microflora β-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride. Cancer Chemother. Pharmacol. 42 (1998) 280-286
159. Kehrer D.F.S., Sparreboom A., Verweij J., de Bruijn P., Nierop C.A., van de Schraaf J., Ruijgrok E.J., and de Jonge M.J.A. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin. Cancer Res. 7 (2001) 1136-1141
160. Kadlubar F.F., Miller J.A., and Miller E.C. Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res. 37 (1977) 805-814
161. Moore B.P., Hicks R.M., Knowles M.A., and Redgrave S. Metabolism and binding of benzo(a)pyrene and 2-acetylaminofluorene by short-term organ cultures of human and rat bladder. Cancer Res. 42 (1982) 642-648
162. Frederickson S.M., Hatcher J.F., Reznikoff C.A., and Swaminathan S. Acetyl transferase-mediated metabolic activation of N-hydroxy-4-aminobiphenyl by human uroepithelial cells. Carcinogenesis 13 (1992) 955-961
163. Kadlubar F.F., Unruh L.E., Flammang T.J., Sparks D., Mitchum R.K., and Mulder G.J. Alteration of urinary levels of the carcinogen, N-hydroxy-2-naphthylamine, and its glucuronide in the rat by control of urinary pH, inhibition of metabolic sulfation, and changes in biliary excretion. Chem. Biol. Interact. 33 (1981) 129-147
164. Rothman N., Talaska G., Hayes R.B., Bhatnagar V.K., Bell D.A., Lakshmi V.M., Kashyap S.K., Dosemeci M., Kashyap R., Hsu F.F., Jaeger M., Hirvonen A., Parikh D.J., Davis B.B., and Zenser T.V. Acidic urine pH is associated with elevated levels of free urinary benzidine and N-acetylbenzidine and urothelial cell DNA adducts in exposed workers. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 1039-1042
165. Kaderlik K.R., Mulder G.J., Turesky R.J., Lang N.P., Teitel C.H., Chiarelli M.P., and Kadlubar F.F. Glucuronidation of N-hydroxy heterocyclic amines by human and rat liver microsomes. Carcinogenesis 15 (1994) 1695-1701
166. 2-glucuronide conjugate of 2-hydroxyamino-MeIQx un urine. Cancer Res. 59 (1999) 5154-5159
167. Malfatti M.A., and Felton J.S. N-glucuronidation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N-hydroxy-PhIP by specific human UDP-glucuronosyltransferases. Carcinogenesis 22 (2001) 1087-1093
168. 2-glucuronide conjugate of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine in urine and its relationship to CYP1A2 and NAT2 activity levels in humans. Carcinogenesis 23 (2002) 831-838
169. Dietrich C.G., de Waart D.R., Ottenhoff R., Bootsma A.H., van Gennip A.H., and Oude Elfernik R.P.J. Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis 22 (2001) 805-811
170. Malfatti M.A., Ubick E.A., and Felton J.S. The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Carcinogenesis 26 (2005) 2019-2028
171. Kaderlik K.R., Mulder G.J., Shaddock J.G., Casciano D.A., Teitel C.H., and Kadlubar F.F. Effect of glutathione depletion and inhibition of glucuronidation and sulfation on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism, PhIP-DNA adduct formation and unscheduled DNA synthesis in primary rat hepatocytes. Carcinogenesis 15 (1994) 1711-1716
172. Maiden L., Thjodleifsson B., Theodors A., Gonzales J., and Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule endoscopy. Gastroenterology 128 (2005) 1172-1178
173. Beck W.S., Schneider H.T., Dietzel K., Nuernberg B., and Brune K. Gastrointestinal ulcerations induced by anti-inflammatory drugs in rats. Arch Toxicol. 64 (1990) 210-217
174. Atchison C.R., West A.B., Balakumaran A., Hargus S.J., Pohl L.R., Davis D.H., Aronson J.F., Hoffman W.E., Shipp B.K., and Treinen-Molsen M. Drug enterocyte adducts: possible causal factor for diclofenac enteropathy in rats. Gastrornterology 119 (2000) 1537-1547
175. Wax J., Clinger W.A., Varner P., Bass P., and Winder C.V. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 58 (1970) 772-780
176. Sigthorsson G., Tibble J., Hayllar J., Menzies I., Macpherson A., Moots R., Scott D.L., Gumpel M.J., and Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut 43 (1998) 506-511
177. Seitz S., and Boelsterli U.A. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterol 115 (1998) 1476-1482